Alpha-1 Antichymotrypsin (ACT) is an acute phase protein synthesised in the liver. Within the human body it inhibits the activity of proteases such as cathepsin by cleaving them into a different shape or conformation. This activity protects some tissues, such as the lower respiratory tract, from damage caused by proteolytic enzymes. ACT has a number of different uses in clinical diagnostics. Elevated serum levels of ACT are seen during inflammation and reduced serum levels have been associated with liver disease. It has also been associated with the pathogenesis of Alzheimer’s disease as it enhances the formation of amyloid-fibrils in this disease. Within the human body ACT binds with Prostate specific antigen (PSA) to for a PSA-ACT complex. This is used as an indicator of tumor mass and clinical stage of prostate cancer.
| Abbreviation | ACT |
| Molecular Weight | 55 - 68 kDa |
| Variant Name | Product Code | Purity | |
|---|---|---|---|
+ |
Alpha-1-Antichymotrypsin, ultra pure | P159-0 | Ultra Pure |
+ |
Alpha-1-Antichymotrypsin, pure | P159-5 | Pure |